한글목차

AMG0001(COLLATEGENE)은 재생의료 제품으로, 주성분은 HGF cDNA를 포함한 5181 염기쌍의 HGF 유전자를 암호화하는 플라스미드 DNA(Beperminogene Perplasmid)입니다. 폐색성 동맥경화증(ASO) 또는 버거병의 CLI를 치료하는 것을 목표로 합니다. 의약품과 마찬가지로 약리학적 치료 효과를 기대하며 개발되었습니다. 콜라테젠을 허혈 부위 인근 근육에 주사하여 HGF 생성 및 방출을 통한 혈관신생을 유도하고 혈관 수와 혈류를 증가시켜 허혈성 사지 상태를 개선할 것으로 기대되며, ASO 및 버거씨병 환자의 중증 사지 허혈 치료제로 여겨지고 있습니다.

앞으로 몇 년동안 말초동맥질환(PAD) 시장 시나리오는 전 세계적으로 광범위한 조사와 의료비 지출 증가로 인해 변화할 것입니다. 각 회사는 질병을 치료/개선하기 위한 새로운 접근법에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, AMG0001의 우위에 영향을 미칠 수 있는 기회를 모색하고 있으며, 가까운 미래에 PAD에 대한 다른 신흥 제품이 AMG0001과 치열한 시장 경쟁을 벌일 것으로 예상됩니다, 후발 신약이 출시될 경우 시장에 큰 영향을 미칠 것으로 예상됩니다.

이 보고서는 주요 6개국의 말초동맥질환(PAD) AMG0001 시장에 대해 조사했으며, 시장 개요, 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등의 정보를 전해드립니다.

목차

제1장 보고서 서론

제2장 PAD AMG0001 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신흥 치료법)

제5장 AMG0001 시장 평가

• PAD AMG0001 시장 전망
• 주요 6개국 분석
  • 주요 6개국 PAD AMG0001 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight에 대해

제12장 보고서 구입 옵션

영문목차

"AMG0001 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about AMG0001 for Peripheral Artery Disease (PAD) in the six major markets. A detailed picture of the AMG0001 for PAD in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom for the study period 2019 -2032 is provided in this report along with a detailed description of the AMG0001 for PAD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the AMG0001 market forecast analysis for PAD in the 6MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in PAD.

Drug Summary:

AMG0001 (COLLATEGENE) is a regenerative medical product, and its main component is a plasmid DNA encoding the HGF gene of 5181 base pairs, containing the cDNA for HGF (Beperminogene Perplasmid). It is intended to treat the CLI of arteriosclerosis obliterans (ASO) or Buerger's disease. It was developed with an expectation of its pharmacological therapeutic effects, as with pharmaceuticals. COLLATEGENE administered by injection into muscles near the ischemic focus is expected to induce angiogenesis through HGF production/release and improve the ischemic state of the limb by increasing the number of blood vessels and blood flow. It is considered therapeutic in treating critical limb ischemia in patients with ASO or Buerger's disease.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the AMG0001 description, mechanism of action, dosage and administration, research and development activities in Peripheral Artery Disease (PAD).
• Elaborated details on AMG0001 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the AMG0001 research and development activities in PAD across the United States and Europe.
• The report also covers the patents information with expiry timeline around AMG0001.
• The report contains forecasted sales of AMG0001 for PAD till 2032.
• Comprehensive coverage of the late-stage emerging therapies for PAD.
• The report also features the SWOT analysis with analyst views for AMG0001 in PAD.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

AMG0001 Analytical Perspective by DelveInsight

• In-depth AMG0001 Market Assessment

This report provides a detailed market assessment of AMG0001 for Peripheral Artery Disease (PAD) in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom. This segment of the report provides forecasted sales data from 2026 to 2032.

• AMG0001 Clinical Assessment

The report provides the clinical trials information of AMG0001 for PAD covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Peripheral Artery Disease (PAD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence AMG0001 dominance.
• Other emerging products for PAD are expected to give tough market competition to AMG0001 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of AMG0001 in PAD.
• Our in-depth analysis of the forecasted sales data of AMG0001 from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the AMG0001 in PAD.

Key Questions:

• What is the product type, route of administration and mechanism of action of AMG0001?
• What is the clinical trial status of the study related to AMG0001 in Peripheral Artery Disease (PAD) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the AMG0001 development?
• What are the key designations that have been granted to AMG0001 for PAD?
• What is the forecasted market scenario of AMG0001 for PAD?
• What are the forecasted sales of AMG0001 in the six major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom?
• What are the other emerging products available and how are these giving competition to AMG0001 for PAD?
• Which are the late-stage emerging therapies under development for the treatment of PAD?

Table of Contents

1. Report Introduction

2. AMG0001 Overview in PAD

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. AMG0001 Market Assessment

• 5.1. Market Outlook of AMG0001 in PAD
• 5.2. 6MM Analysis
  • 5.2.1. Market Size of AMG0001 in the 6MM for PAD
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of AMG0001 in the United States for PAD
  • 5.3.2. Market Size of AMG0001 in Germany for PAD
  • 5.3.3. Market Size of AMG0001 in France for PAD
  • 5.3.4. Market Size of AMG0001 in Italy for PAD
  • 5.3.5. Market Size of AMG0001 in Spain for PAD
  • 5.3.6. Market Size of AMG0001 in the United Kingdom for PAD

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options